Menu
← Oncology Approval Tracker
FDA DECISION ·
Keytruda + gemcitabine + cisplatin
pembrolizumab + gemcitabine + cisplatin · Merck
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
For locally advanced unresectable or metastatic biliary tract cancer in combination with gemcitabine and cisplatin.
LAMPGEN ANALYSIS
Why it matters
The decision added a checkpoint inhibitor to a chemotherapy backbone for advanced biliary tract cancer.
What research teams should watch
Capture the primary biliary site, extent of disease and chemotherapy readiness when matching patients to the evidence.
PRIMARY RECORDS